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----- LEADING EDGE OF MEDICINE-A REVIEW 
Methods for assessing cell-mediated immunity 
in infectious disease resistance and in the 
development of vaccines 
Nancy E. Coe Clough, DVM, PhD, and James A. Roth, DVM, PhD 
I mmunologic evaluation of vaccines has de-pended largely on the measurement of an anti-
body response in the serum of recipient animals. 
This approach , which worked well for diseases pre-
vented in large part by humoral immunity, ignored 
the contributions cell-mediated immunity (CMI) or 
mucosal immunity make to providing protection 
against many infectious diseases. As a result of this 
approach, certain vaccines were marketed that pro-
duced a satisfactory antibody response but failed to 
protect vaccinates in the field from disease. In the 
modem biologics industry, there is increasing pres-
sure for vaccine improvements and new techno-
logic advancements to be based on a sound under-
standing of the entire basis for immunity, including 
cell-mediated, mucosal, and humoral immunity 
that develops after exposure to infectious disease 
agents. 
Historically, the role of antibodies in the de-
velopment of immunity against most diseases of vet-
erinary importance has been studied more exten-
sively than has the role of CMt ; however, our 
knowledge of cell-mediated immune processes and 
our technologic capability for study of them has 
expanded rapidly in recent years. Currently, a con-
siderable amount of research is aimed at character-
izing CMI. In a rational immunologic approach to 
vaccine development, some questions must be ad-
dressed when assessing the development of CMI 
against a specific disease. Does CMl have an impor-
tant role in providing protection against the dis-
ease? What are the CM! responses that develop after 
vaccination or natural infection with the infectious 
agent, and how can these responses be measured7 
Which antigenic components of the infectious 
agent are targets of the protective CM! responses? 
Which CM! effector functions provide protection 
against the disease? What vaccination strategy (an-
tigen delivery system, adjuvant formulation) in-
duces the most protective CM I response against the 
infectious agent? 
From the National Veterinary Services Laboratories, USDA-
APHIS-VS, PO Box 844, Ames, IA 500 10 (Clough), and the 
Department of Microbiology, Immunology, and Preventive Med-
icine, Iowa State University, Ames IA 50011 (Roth) 
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Importance of CMI in Providing 
Protection Against Specific Diseases 
The importance of CMI against a specific dis-
ease sometimes is studied by determining that in-
duction of an active antibody response or the ac-
quisition of passively acquired antibody to the 
causative agent does not correlate well with protec-
tion against the disease. With this approach, it is 
often assumed that if antibodies do not prevent 
signs of disease, then other immune mechanisms 
(cell-mediated or mucosa!) must be important for 
protective immunity. In some viral diseases, such 
as African swine fever, 1 antibodies are nonneutral-
izing and coexist with virus in the serum. In these 
cases, CM! responses or other immune mechanisms 
are assumed to be critical for protective immunity. 
In diseases such as pseudorabies in swine,2 neu-
tralizing antibodies may be generated systemically 
and may be effective against viremia, but a corre-
lation has not been detected between the concen-
trations of antibodies detected in mucosa] or tra-
cheal washings and protection against localized 
virus challenge-exposure. In such diseases, cell-me-
diated, mucosa!, and humoral immunity may all 
play important roles in protective immunity. 
The correlation between antibody concentra-
tions and disease protection may vary depending 
on the model used to study specific immunity. An-
tibodies to bluetongue virus may protect against 
homotypic, but not heterotypic, virus challenge-ex-
posure3; a similar mechanism may exist for equine 
influenza virus.4 Antibodies to rotavirus are de-
tected inconsistently in the serum , 5·6 making it dif-
ficult to assess the correlation between humoral im-
munity and disease protection , but suggesting that 
immune mechanisms other than antibody produc-
tion may be important. Protective immunity to 
Pseudomonas aeruginosa can be induced in mice that 
do not have evidence of a concurrent antibody re-
sponse. 7 Antibodies in the serum appear to play a 
role in providing protection against P aeruginosa, but 
are not essential for protective immunity. 
The importance of CMI in providing protection 
against specific diseases may also be assessed by sup-
pressing a specific arm of the immune system and 
evaluating the severity of disease after subsequent 
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challenge exposure. Pharmacologic suppression of 
CMI responses may be achieved by treating animals 
with drugs such as cyclosporine A. Treatment of 
research subjects with cyclosporine A, which spe-
cifically inhibits a key cytokine (ie, interleukin-2) 
necessary for T-lymphocyte proliferation, has been 
used to determine the importance of T-lympho-
cytes in the control of numerous diseases.8-10 Se-
lective immunosuppression may also be achieved 
by surgical removal of primary lymphoid tissues. 
Removal of the thymus at the time of birth elimi-
nates most T-lymphocytes. Humoral immunity may 
be effectively suppressed in avian species by re-
moval of the bursa of Fabricius, which is the site 
of B-lymphocyte differentiation, at the time of 
hatching. 11 Immunologic responses after thymec-
tomy or bursectomy have been compared to deter-
mine the relative importance of humoral immunity 
and CMI against diseases of birds, such as neural 
lymphomatosis. 12 Although drug administration 
and surgery can be useful tools in the study of CM!, 
the immunosuppressive effects associated with 
their use tend to be broad and are not always well-
defined. The T- and B-lymphocytes interact to gen-
erate a complete antibody response, so generalized 
T-cell suppression also is likely to have an impact 
on antibody production. 13 Immunosuppression in-
duced by anti-lymphocyte antibodies is more spe-
cific than that induced by drugs and surgery, be-
cause only cells possessing the cell surface marker 
targeted by the antibodies are eliminated, leaving 
phenotypically distinct lymphocytes and surround-
ing tissues intact. Anti-lymphocyte antibodies may 
be directed against a cell surface marker common 
to all T-lymphocytes,14 or they may be directed 
against specific T-lymphocyte subsets. 15 
Measurement of Antigen-specific CMI 
Function 
Once it has been established that CMI is im-
portant in providing protection against a specific 
disease agent, measurement of CMI can be accom-
plished by several methods. Some methods are gen-
eral in nature. That is, in their unmodified forms, 
they may detect a cellular response to microbial 
exposure, but may not offer information as to the 
specific cell populations involved and may not iden-
tify the specific microbial antigens that elicited the 
cellular response. Other methods measure a spe-
cific effector function of CM! (cytotoxicity or release 
of specific cytokines). 
Delayed-type hypersensitivity (DTHJ assay-One 
of the first assays of CM! function that was reported 
is the DTH assay. The best known example of a DTH 
assay is the official screening test for tuberculosis. 
Animals previously exposed to tuberculosis-causing 
Mycobacterium organisms develop a localized swell-
ing 48 to 72 hours after intradermal injection with 
tuberculin antigens. 16 The swelling is composed 
largely of macrophages and other mononuclear 
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cells attracted to the injection site by soluble sub-
stances, called cytokines, that are released from 
sensitized antigen-specific lymphocytes. 
Delayed-type hypersensitivity assays have been 
used to measure CM! responses to bacteria, 17 .1 8 vi-
ruses, 19-21 rickettsiae,22·23 mycoplasmas,24 and pro-
tozoa.25 Delayed-type hypersensitivity assays are a 
popular means for measuring CM! responses, be-
cause they are economical to perform and do not 
require sophisticated laboratory equipment. They do, 
however, require careful and consistent antigen 
preparation, intradermal injection technique, and 
lesion interpretation. Delayed-type hypersensitivity 
assays can be a qualitative test in that they can dif-
ferentiate sensitized animals from nonsensitized ones, 
but they also can be semiquantitative if the mag-
nitude of the CMI response is correlated with the 
size of the resultant swelling. In a report, lesion size 
has been correlated with the magnitude of protec-
tion 18; however, other reports have not detected a 
strong correlation between lesion size and amount 
of protectionn·24 
Leukocyte migration inhibition assay-Leukocyte 
migration inhibition tests are another means of 
measuring CM! activity. In these assays, prepara-
tions of leukocytes are incubated with antigen, 
which stimulates sensitized T-lymphocytes in the 
preparations to release cytokines. Certain cytokines 
released by the lymphocytes inhibit leukocyte mo-
tility, a property that, in vivo, serves to enhance 
deposition of inflammatory cells in areas of infec-
tion. The movement of leukocytes under an agarose 
gel20-26 or out of a capillary tube27 is measured and 
compared with movement of a similar population 
of cells that were not stimulated with antigen. 
Cytokines responsible for inhibiting leukocyte 
migration probably also play a role in the generation 
of DTH lesions, but CM! responses detected by the 2 
assays do not always correlate well.26 The leukocyte 
migration inhibition assay, like the DTH assay, is rel-
atively simple and economical to perform. It has 
been used successfully with leukocytes obtained 
from the blood of several mammalian species.28-31 It 
is used frequently in studies in birds26·27·32.33 and 
may be more sensitive than DTH assays for the de-
tection of CM! in chickens.34 
Adoptive transfer assays-Adoptive transfer as-
says measure the ability of sensitized lymphocytes 
from an immune animal to confer immunity to a 
naive animal.35 just as the administration of serum 
obtained from an immune animal to a naive animal 
provides passive immunity to diseases in which hu-
moral immunity plays a substantial role in protec-
tion, so can lymphocyte transfer provide passive pro-
tection to diseases in which CM! plays an important 
role. After the lymphocytes are administered to the 
recipient animal, the effect is usually measured as 
resistance to challenge exposure,36·37 but may be 
assessed through DTH38 or some other functional 
assay. 
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An animal possesses numerous subsets of lym-
phocytes, each with a unique phenotype. Infectious 
agents may preferentially stimulate certain lympho-
cyte subsets. Lymphocyte subsets responsible for 
protective CMI can be detected by the use of an adop-
tive transfer assay in which the donor lymphocytes 
are fractionated prior to transfer. Donor lympho-
cytes can be enriched to contain specific lympho-
cyte subsets by lysing contaminating lymphocytes 
with specific antiserum,39·40 or flow cytometry can 
be used to purify lymphocyte subsets expressing 
differentiating surface molecules.41 
One of the major complications of adoptive 
transfer assays is that donor and recipient animals 
must be matched for major histocompatibihty com-
plex (MHC) antigens, or the transfered lymphocytes 
will be rejected by the recipient animal. This is an 
easy obstacle to overcome in mice in which highly 
inbred, MHC-matched strains are available, but it 
makes studies in conventional animals difficult. 
Adoptive transfer studies have been performed, us-
ing chimeric twin calves42 and monozygotic twin 
lambs,43 but the limited availability of such twins 
makes this approach impractical for widespread use. 
Lymphocyte proliferation assays-Proliferation 
assays are widely used as a means of measuring 
CM!. Cellular proliferation is important in vivo for 
the expansion of reactive lymphocyte populations. 
In animals that have not developed CMI to a specific 
antigen, the number of lymphocytes specific for that 
antigen is low. Animals that have developed CMI 
against a specific antigen have an increase in the 
number of circulating lymphocytes that recognize 
the antigen. Exposure of these lymphocytes to that 
antigen will cause them to undergo mitosis and se-
crete cytokines. In proliferation assays, lympho-
cytes harvested from vaccinated or infected animals 
are incubated with the antigen that is being stud-
ied.44 After incubating the lymphocytes for several 
days, radioactive (tritiated) thymidine is added to 
the lymphocytes being cultured. Lymphocytes that 
are actively dividing, and thus producing DNA, will 
incorporate the radioactive thymidine into new DNA 
molecules. The amount of radioactivity associated 
with the lymphocytes after nonincorporated thymi-
dine is washed away is proportional to the amount 
of mitotic activity of the lymphocytes. Results usu-
ally are expressed as a ratio (stimulation index) of 
the radioactivity in antigen-exposed lymphocytes to 
that in nonantigen-exposed lymphocytes from the 
same animal. Colorimetric methods also have been 
developed to detect mitotic activity.45 
Proliferation assays are technically more com-
plex than the assays discussed previously. Lympho-
cytes must be cultured for several days, and viabil-
ity of the cells must remain high during this period. 
Special safety precautions must be observed when 
working with radioactive thymidine, and expensive 
instrumentation is required to measure the radio-
activity in lymphocyte samples. 
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Proliferation assays have been used successfully 
to measure antigen-specific CMI responses against 
numerous infectious agents in animals. Although 
proliferation assays are adaptable to nearly every 
experimental situation, special attention must be 
paid to antigens that are intrinsically mitogenic to 
lymphocytes. Mitogenic antigens stimulate prolif-
eration of lymphocytes, regardless of the lympho-
cytes' antigenic specificity. Proliferation assays may 
not be desirable as a means of studying antigen-
specific CMI responses to strongly mitogenic anti-
gens because of high nonspecific (background) ra-
dioactivity values. 
Although proliferation assays are used to meas-
ure one feature of the cellular immune response, 
they are still somewhat nonspecific, because the ef-
fector function of the proliferating cells is not de-
termined. Proliferation itself does not imply that a 
protective immune response is being generated. 
Clonal expansion of lymphocytes with suppressor 
activity and of cytotoxic lymphocytes may yield 
similar proliferation assay results, yet each response 
has a different influence on the overall immune re-
sponse. 
Cytokine release assays-Cytokine release by ac-
tivated lymphocytes may be assayed as a measure 
of CM!. In the assays that were described previously 
in this report, cytokine release is needed to achieve 
a measurable response (cutaneous swelling, leuko-
cyte migration inhibition, or lymphocyte prolifera-
tion), but the specific cytokines involved are not 
characterized by the assay. Many cytokines, work-
ing alone or in combination with other cytokines, 
cause specific cellular responses, and cytokine re-
lease assays identify those cytokines that are active 
in CMI responses to a specific infectious agent. Cy-
tokine assays may be bioassays, which measure the 
effect that specific cytokines have on a defined bio-
logic system. They may measure cytokine concen-
trations directly, as in ELISA, radioimmunoassays, or 
precipitation assays, or they may detect cytokine-
specific mRNA in lymphocytes. 
One form of bioassay uses cytokine-dependent 
cell lines. These cells have been adapted in the lab-
oratory so that they require a specific cytokine for 
proliferation. Addition of test fluids containing that 
specific cytokine to a culture of cytokine-dependent 
cells causes the cells to proliferate in a dose-depend-
ent manner. Cellular proliferation then can be quan-
titated by the use of tritiated thymidine or colorimet-
ric methods. Concentrations of cytokine in test fluids 
can be determined by correlating the amount of cel-
lular proliferation to a value on a standardized dose-
response curve. Bioassays are advantageous, because 
only biologically active cytokines are measured. A 
limitation of this type of bioassay is the availability of 
the appropriate cytokine-dependent cell line. Cell 
lines specific for interleukin-146 and interleukin-247 
of human beings have been developed, as have cell 
lines specific for a number of cytokines of mice.48 The 
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specificity of bioassays must be carefully evaluated; 
contaminating cytokines may have costimulatory or 
inhibitory actions on the cell lines of the bioassay 
system that could affect accurate measurement of the 
principal cytokine. 
Alternate bioassays have been described for the 
measurement of cytokines that have well-defined, 
unique actions. Interferon may be assayed by its 
ability to inhibit virus infection of cells.49 The abil-
ity to lyse certain fibroblast cell lines forms the ba-
sis of a bioassay for tumor necrosis factor ; this assay 
has been adapted for use in swine .50 However, 
many cytokines have nonexclusive actions that are 
too generalized to be measured by this type of bio-
assay. 
Direct cytokine assays are more specific and 
subject to fewer environmental variables than bio-
assays, but they are currently available for only a 
few well-characterized cytokines.48•51 Development 
and use of direct cytokine assays are limited by the 
availability of necessary assay reagents. Specific an-
tibodies are needed to detect cytokines in direct as-
says, and a purified source of cytokine is highly 
desirable as a control antigen. Most cytokines of 
human beings and mice have been purified and 
cloned for large-scale in vitro production, so abun-
dant sources of cytokine and cytokine-specific an-
tibodies are available for these species. However, 
reagents needed for most direct cytokine assays for 
animals of veterinary importance are not yet readily 
available. It is likely that as species-specific reagents 
for cytokines of domestic animals become more 
readily available , direct assays will complement bio-
assays as methods of measuring cytokine release in 
veterinary applications. 
Detection of mRNA molecules that encode cy-
tokine proteins has been gaining in popularity as a 
method of measuring cytokine production . Cyto-
kine-specific mRNA is produced by activated lym-
phocytes and has been detected in lymphocytes of 
ruminants within 4 hours after activation.52 How-
ever, expression of cytokine-specific mRNA by lym-
phocytes is transient; this must be considered when 
interpreting assay results. In assays that measure 
RNA, mRNA specific for the cytokine being studied 
is detected by use of a nucleic acid probe that is 
designed to have a sequence of bases complemen-
tary to that of the cytokine-specific RNA. The probe 
is labeled, usually with radioactive phosphorous or 
biotin, so that cytokine-specific RNA can be detected 
and quantitated. 
Cytotoxicity assays-Cytotoxicity assays meas-
ure the ability of lymphocytes to kill target cells. Cy-
totoxic T-lymphocytes are especially important in 
the control of viral diseases, although they also play 
a role in the immunity of hosts to facultative intra-
cellular bacteria. 53 Infected cells that express viral 
or microbial proteins on their cell surfaces in as-
sociation with MHC antigens are destroyed by cy-
totoxic T-lymphocytes. 
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The most common cytotoxicity assay currently 
in use is a chromium release assay54 In this assay, 
lymphocytes are incubated with target cells that 
have been labeled with radioactive chromium. Tar-
get cells for antigen-specific CM! responses must be 
histocompatibility matched with the putative cyto-
toxic I-lymphocytes, and then are infected with the 
agent being studied. Radioactive chromium is re-
leased into the surrounding cell culture medium as 
the labeled target cells are lysed by the cytotoxic lym-
phocytes, and the amount of radioactivity in the 
medium after cell debris is removed is proportional 
to the amount of cytotoxic activi ty. An esterase as-
say that detects granules released by active cyto-
toxic lymphocytes has been developed as a nonra-
dioactive alternative to chromium release assays. 55 
Cytotoxicity assays yield valuable information, 
because the effector function that they measure is 
usually, but not always, associated with protective 
immunity. Cytotoxicity assays are prone to the same 
difficulties as adoptive transfer assays in that the 
cytotoxic activity of I-lymphocytes is usually MHC 
restricted, so target cells must be matched with the 
lymphocytes being tested. Furthermore, the chro-
mium release assay, like the tritiated thymidine 
proliferation assay , uses radioactive substances; 
however, radioactive chromium emits )'-rays that 
are more penetrating than the ex-rays emitted by 
tritium and, therefore, requires additional safety 
precautions for handling and disposal. Cytotoxicity 
assays may not be suitable for all infectious agents; 
for agents that are highly cell-associated, such as 
herpesvirus of chickens,56 it may be impossible to 
harvest enough free virus to infect a sufficient num-
ber of target cells. 
Comparison of in vivo and in vitro assays- All 
of the assays reported here provide useful infor-
mation about CM! function. However, no assay alone 
provides a complete view of CM! responses. It is 
important when characterizing the CM! response 
against a specific infectious agent to look at the 
results of several assays, each measuring a different 
aspect of CM!. 
In vivo assays (DTH and adoptive transfer) in 
their simplest forms yield little information regard-
ing specific CM! effector mechanisms that are active 
in protective immunity; however, they are advan-
tageous, because immune responses are observed 
in the context of the entire animal. Adoptive trans-
fer assays have an additional advantage, because re-
sistance to challenge exposure, the final determi-
nant of successful immunization, is usually meas-
ured directly. 
In vitro assays tend to be more specific than 
in vivo assays. They can be designed so that only 
a narrow, defined population of cells is assayed and 
so that only a single effector function is assessed . 
In vitro assays also are useful to assess the devel-
opment of CMI responses with time after exposure 
to an infectious agent. Because actual assays are 
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performed outside of animals, repeated tests can be 
performed that use lymphocytes obtained from the 
same animal. Each animal may be used only once 
for in vivo assays, because immune responses elic-
ited as a result of the initial assay may influence 
responses in subsequent assays. Increasingly, in vi-
tro assays are used to define molecular bases of 
antigen-specific CMI responses, but it is important 
to recognize that complex cell-cell interactions exist 
in host animals and that, in vivo, multiple effector 
functions work concurrently to achieve protective 
immunity. Conclusions drawn from results of in 
vitro assays should always be compared with the 
development of in vivo resistance to challenge ex-
posure. 
Cell-mediated Immunity After Natural 
Infection vs After Vaccination 
One cannot assume that the CMI response 
measured after natural infection is the same as that 
induced by vaccination. Modified-live vaccines are 
the most likely to mimic natural infection, because 
they replicate in the recipient animal. When foreign 
proteins are actively synthesized during microbial 
or viral replication in infected host cells, they are 
processed by a different intracellular pathway than 
that by which exogenous internalized proteins are 
degraded. Proteins processed by the endogenous 
pathway are expressed on infected cell surfaces in 
conjunction with MHC class I molecules, which 
makes them the target of MHC class I-restricted cy-
totoxic effector cells. 57 For certain vaccines, such as 
varicella-zoster,58 it has been reported that re-
sponder cell frequencies , target antigens, and effec-
tor functions are similar between vaccinates and 
naturally infected human beings; however, in a 
study of the development of immunity to Brucella 
abortus , vaccination with modified-live vaccine in-
duced weaker proliferation responses in cattle than 
infection with a low-virulence isolate of B abortus. 59 
Killed vaccines and bacterins often are assumed 
to be less immunogenic than their live counter-
parts. Diminished CM! responses have been docu-
mented for killed vaccines of bluetongue virus,60 
Salmonella typhimurium,49 Listeria monocytogenes,6 1 
and Rickettsia sp,23 compared with natural infection 
or live vaccines. However, there are a number of 
other killed vaccines, including those containing 
rotavirus,62 equine infectious anemia virus,63 and 
foot-and-mouth disease virus,64 that induce CM! re-
sponses similar to natural infection. Some killed 
vaccines (rabies virus,19 FeLV,65 Brucella subunit66) 
have been reported to elicit greater CMI responses 
than natural infection. In some of these cases, how-
ever, the enhanced CM! response after vaccination 
can be attributed to the fact that the organism in a 
natural infection is immunosuppressive, but the 
vaccine is not. The adjuvant system used in a killed 
vaccine can also have a major influence on the de-
velopment of CMI responses. 17,67 
The duration of vaccine-induced CMI may dif-
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fer from the duration of CM! induced by natural in-
fection. Typically, the duration of vaccine-induced 
immunity has not been well-defined. Most veteri-
nary vaccine studies have detected initial vaccine 
efficacy, but researchers have not monitored im-
mune responses beyond several weeks after vacci-
nation.68·69 In studies on human beings, data re-
garding duration of immunity are sometimes gath-
ered indirectly through epidemiologic studies.70 In 
nearly all of the reported studies, however, protec-
tive immunity over time is determined by chal-
lenge-exposure or serologic methods71 ·72; currently, 
few studies have measured CMI responses over an 
extended period. 
Identification of Microbial Antigens 
that Induce Protective CMI 
Identification of protective microbial antigens 
is important in implementing a rational immuno-
logic approach to vaccine development. Knowledge 
of protective antigens facilitates the selection of vac-
cine strains for whole-cell vaccines; the strain must 
express the protective antigens and stimulate solid 
immunity to those antigens. However, vaccination 
with whole live organisms, in some instances, may 
not be safe, and products containing whole-cell killed 
oganisms may not be efficacious. In these cases, 
subunit vaccines or live recombinant vectored vac-
cines may be used , both of which contain only se-
lected antigens from the microbial agent in the 
form of preformed antigen(s) (subunit) or as a 
cloned gene in a replicating nonpathogenic bacte-
rium or virus (vectored vaccines). Careful selection 
of the appropriate antigens for inclusion in these 
vaccines is critical to the efficacy of the final prod-
uct. 
The type of antigen that elicits a protective im-
mune response varies widely among infectious a-
gents. For some organisms, such as cytomegalovi-
rus,73 one or a few antigens are dominant and are 
the targets of most of the host 's immunoreactivity. 
With other organisms, such as rotavirus74 or herpes 
simplex virus,75 immunoreactivity is broad-based 
and directed against several antigens. Surface pro-
teins and glycoproteins are the targets of immune 
responses for numerous agents, including rabies vi-
rus,76 pseudorabies virus,77 respiratory syncytial vi-
rus,78 rotavirus,74 and bordetellae.75 Antigens lo-
cated on the surface of extracellular organisms or 
expressed on the surface of infected host cells are 
likely candidates to be targets of immune responses, 
because they are readily accessible to antibodies or 
lymphocyte antigen receptors; however, sometimes 
internal proteins, such as those of influenza virus,79 
are processed so that they are expressed on host 
cell surfaces and are the main targets for cytotoxic 
I-lymphocytes. Cytotoxic I-lymphocytes that are 
targeted against nonstructural proteins, such as the 
secreted gX protein of pseudorabies virus,77 and 
against nonconstitutively expressed proteins (pro-
teins not expressed under all conditions), such as 
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stress-induced catalase II protein of S typhimurium ,80 
also have been identified. 
The assays described previously can be modi-
fied to identify proteins that are protective. Instead 
of vaccinating with a whole-cell preparation, semi-
purified microbial extracts49·81.82 or purified pro-
teins74·83 can be injected, and the CM! response can 
be evaluated. Alternatively, deletion mutant vaccines 
can be used, and the CMI response in the absence 
of the antigen under study can be evaluated. If the 
physical structures of the antigens of an infectious 
agent are known, computer analyses of the struc-
tures may be helpful to identify potential antigens 
that may stimulate protective immune responses. 
Computer programs that are developed on the basis 
of knowledge of the antigenic structures that stim-
ulate I-cell responses in other organisms can be 
used to predict potential I-cell reactive sites on an-
tigens in infectious agents being studied.84 
Different antigens may be targets for different 
lymphocyte subsets. It has been reported that MHC 
class I-restricted cytotoxic I-lymphocytes of mice 
are directed against glycoprotein gC of herpes sim-
plex virus and that glycoprotein gD is the target for 
MHC class II-restricted cytotoxic cells.85·86 Cytotoxic 
I-lymphocytes directed against different antigens may 
exhibit different reactivities; cytotoxic I-lympho-
cytes against the G protein of vesicular stomatitis 
virus are serotype specific, whereas cytotoxic T-
lymphocytes against the internal (N) protein are 
cross-reactive. 79 
Methods of Antigen Delivery that 
Stimulate CMI 
The method of antigen delivery may be as crit-
ical to the efficacy of a vaccine as the selection of 
protective antigens to include in the vaccine . Anti-
gen presentation influences the types of immune 
responses that are generated in host animals, and 
the type of immunity favored should correspond to 
the immune mechanisms that have been identi fied 
as protective. By themselves, purified antigens often 
are poorly immunogenic , which complicates the de-
velopment of subunit or single antigen vaccines. Ar-
eas of research aimed at increasing the CM! response 
to vaccines include improved adjuvant formulation, 
generation of vaccine vectors, and the development 
of bioengineered delivery systems. 
Adjuvants-Adjuvants are substances that en-
hance the immunogenicity of vaccines. They may act 
to retain the antigen at the injection site (depot ef-
fect) , or they may serve as irritants to promote a 
local inflammatory response and recruit antigen-pre-
senting cells (macrophages) to the area of injection. 
They may improve interactions of the antigen with 
antigen-presenting cells, or they may enhance in-
teractions between antigen-presenting cells and re-
sponding lymphocytes. A number of adjuvants cur-
rently are used in the production of veterinary 
biologicals. Among the most popular are aluminum 
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salts and mineral oil. Although alum and oil emul-
sions enhance antibody responses to vaccines, they 
do not necessarily enhance CM! responses.87 New 
generation adjuvants, such as block copolymers ,87 
specifically enhance CM! responses. Saponins ,53,88.89 
muramyl dipeptide,87·90 and oils complexed to man-
nides or Freund's incomplete adjuvant90 also have 
received renewed interest for their CMI-inducing 
properties. Immunomodulatory cytokines, such as 
interleukin-2,91 ·92 have been used as adjuvants to 
enhance CMI responses. Physical and chemical prop-
erties of the antigens in a particular vaccine may 
influence the formulation of the optimal adjuvant 
for that product.87 Also , some of the most immu-
nostimulatory adjuvants produce unacceptable side 
effects in vaccinated animals. There must be a bal-
ance between the degree of immunoenhancement 
an adjuvant affords and the severity and accepta-
bility of the side effects that it produces in vacci-
nated animals. 
Vectored vaccines-Live recombinant vectored 
vaccines have been developed that stimulate CM! 
responses to heterologous antigens. In this class of 
vaccines, a nonpathogenic vector organism (usually 
a bacterium or virus) is used to produce a specified 
antigen from another infectious agent. The gene en-
coding the antigen of interest is inserted in the DNA 
of the vector organism. As the vector synthesizes 
protein, antigen is produced from the cloned gene 
along with the vector's own antigens. Vaccinia vi-
rus ,93-96 pseudorabies virus,97 S typhimurium,98 and 
Bacillus Calmette-Guerin (M bovis)99.1°0 have been 
used successfully as vectors. S typhimurium-vec-
tored vaccines have promise as oral vaccines be-
cause of the ability of Salmonella organisms to 
invade intestinal tissue and stimulate mucosa! im-
munity.101 Vectored vaccines have the superior im-
munogenicity of a live vaccine and can be used to 
induce immunity to antigens of infectious agents 
for which vaccination with a live product is not 
feasible or not desirable. The replication potential 
of vectored vaccines is especially advantageous for 
antigens that must be actively synthesized within 
the host to induce protective immunity. 
Biodegradable microspheres-Synthetic antigen 
delivery systems that stimulate CM! responses also 
have been developed , including biodegradable mi-
crospheres, liposomes, and immunostimulating com-
plexes (1scoM). Antigens are coated with inert 
synthetic polymers to form microspheres.102 Poly-
mers that are used are similar to those found in 
absorbable suture material. The rate of antigen deg-
radation and, to a certain extent, the anatomic and 
cellular locations where the particles will be depos-
ited are influenced by the size of the microsphere 
particle and the chemical structure of the polymer 
coating. By including particles of different sizes and 
different polymer densities, sustained, slow release 
of antigen can be achieved. Pulsed antigen release 
also can be achieved; this mimics the effect of pri-
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mary and booster vaccinations through a single vac-
cine administration. Microspheres have promise for 
use in oral vaccines, because they protect the an-
tigen from degradation by digestive enzymes and 
from inactivation by colostral antibodies, yet they 
are taken up into lymphoid tissues to effect a local 
or systemic immune response. Proliferative and cy-
totoxic CM! responses have been detected after the 
administration of microsphere vaccines. 103 
Liposomes-Liposomes are created by trapping 
antigen between lipid bilayers. Like microspheres, 
the immunoenhancing properties of liposomes may 
be modified by altering their physical properties. 104 
Lipid membranes themselves often have adjuvant 
properties , but discrete adjuvants also may be in-
corporated, with the antigen or in separate vesicles, 
into liposome vaccines. Synergistic effects may exist 
between adjuvants and liposomal membranes. Li-
posome vaccines may induce DTH, lymphocyte pro-
liferation, and cytotoxic activity when administered 
orally or parenterally. 104 
Immunostimulating complexes-An JSCOM is com-
posed of an adjuvant skeleton, such as saponin-gly-
koalkaloid complexes, into which multiple antigen 
molecules are inserted. 105.l06 By creating a multi-
meric particle of adjuvant and antigen; the anti-
genic complexity that is often necessary for ade-
quate immunogenicity is created. Also, the intimate 
contact between antigen and adjuvant sometimes al-
lows smaller doses of vaccine to be used. An JSCOM 
can induce antigen-specific lymphocyte prolifera-
tion and cytotoxic lymphocyte responses ,107.ios and 
they have been used in vaccines to stimulate local 
(mucosal) and systemic immune responses. 109 
Many diseases require that a CM! response de-
velop in the host to provide adequate immune pro-
tection. Extensive knowledge of the CMI responses 
to infectious agents is required when a rational ap-
proach to improved vaccine development for these 
diseases is attempted. The study of CM! is not as 
straightforward as the study of humoral immunity. 
Several functional assays, some of which are tech-
nically complex, may be performed. Results of the 
assays must be compared with one another and must 
be correlated to protection of the host to enable 
researchers to derive meaningful conclusions re-
garding antigen-specific CM I responses against an 
infectious agent. Once gathered, this knowledge 
can be used to develop and validate vaccines for 
diseases in which CM! responses are required for pro-
tection. 
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